Most importantly, patients with high co-expression of nuclear HDAC3 and cytoplasmic CDH1 had shorter survival times (P < 0.001), more frequent lymph node metastasis (P < 0.001), and advanced clinical stage (P < 0.001). The gene discussed is HDAC3; the disease is metastatic malignant neoplasm in the lymph nodes.